Join over 5,000 professionals who attended Anima's science-driven webinars and stay up-to-date with the latest advances in mRNA regulation
VISUAL BIOLOGY
LIGHTNING.AI PLATFORM
A VISUAL BIOLOGY APPROACH TO DRUG DISCOVERY
MASSIVELY PARALLEL AUTOMATED VISUAL BIOLOGY LAB
TWO BILLION DISEASE PATHWAYS IMAGES
THE WORLD’S LARGEST DATASET OF mRNA BIOLOGY VISUALIZATIONS
THE VISUAL BIOLOGY NEURAL NETWORK
TRAINED TO VISUALLY RECOGNIZE DISEASE MECHANISMS
VISUAL BIOLOGY LLM AND THE LIGHTNING CO-PILOT
WITH MOAi TECHNOLOGY
ELUCIDATE MECHANISMS OF ACTION AND MOLECULAR TARGETS
PIPELINE OF 20 PROGRAMS
BIG PHARMA PARTNERSHIPS

Anima Biotech - Lightning.AI Platform

Visual Biology

Lightning Platform

Anima Biotech is a recognized leader in small molecule mRNA drugs. Validated through strategic collaborations with Lilly, Takeda, and AbbVie, Anima is transforming target and drug discovery with its game-changing TechBio Visual Biology platform, Lightning.AI.

Lightning.AI leverages Anima’s proprietary in-cell pathway visualization technology, PathwayLight™, to run millions of visualizations in high throughput, imaging hundreds of cellular pathways in both healthy and diseased cells. This process generates entirely new, large-scale data drawn directly from the biology of the disease—data no one else has.

Using this data, Lightning.AI trains disease-specific AI models, with neural networks visually learning the difference between healthy and diseased cells, identifying dysregulated pathways—the disease signature. By analyzing these pathways through its Visual Biology Knowledge Graph, Lightning.AI uncovers novel targets backed by experimental validation.

For these targets, Lightning.AI advances through its drug discovery runway to discover smart mRNA drugs - small molecules that visually reverse disease phenotypes by modulating mRNA biology. Lightning.AI continuously builds and evolves proprietary AI models for each disease, generating new data in real time through large-scale visual experimental biology across multiple cell types and disease variants.

This iterative approach empowers pharma companies to develop exclusive franchises with a competitive edge, exploiting evolving models for both target discovery and drug development.

Our Pharma Partners

For partnering inquiries, please contact [email protected].

Lightning Use Cases

Unlike traditional AI, which relies on existing datasets, Lightning.AI generates entirely new, disease-specific data through large-scale experimental biology.

Powered by PathwayLight™ technology, it visualizes cellular pathways in high-throughput and high-content from both diseased and healthy cells. By analyzing millions of these pathways, Lightning.AI trains neural networks tailored to each disease, identifying dysregulated pathways—the true signatures of disease mechanisms.

This approach unlocks an unparalleled understanding of disease biology, revealing novel drug targets previously beyond reach. With its unique ability to generate proprietary deep data from diseased cells—analyzed by neural networks to recognize dysregulated pathways—Lightning.AI is as a transformational platform for multiple applications. These include target discovery, identification of small molecules that modulate mRNA biology, and large-scale visualizations to optimize mRNA vaccines and therapeutics.

A Visual Biology Approach to Drug Discovery

The world's largest dataset of disease pathway visualizations

Over the past decade, working across dozens of drug discovery programs within our pipeline and with partners, we have generated a vast proprietary library of cellular pathway visualizations that drives our platform’s applications. Leveraging AI, we analyze and process over 2 billion images of cellular pathways from multiple diseases across diverse therapeutic areas. Our Visual Biology Knowledge Graph, combined with a large language model, enables advanced querying of this extensive dataset. By bringing AI to large-scale cellular pathway imaging analysis, Lightning.AI makes decoding complex biology possible.

mRNA Lightning™ Platform
Visualizing and Decoding mRNA biology
2 Billion mRNA biology images
mRNA biology knowledge graph
The mRNA image neural network
Identify the mRNA biology signature of disease mechanisms
2 Billion mRNA Biology images analysis
mRNA regulation
curated publications
OMICS
Cis-RNA elements
Thousands of
experimental results
Codon usage analyses

High-Content High-Throughput Platform

Our Visual Biology Lab is a massively parallel, fully automated lab with robotics and high-end microscopy, incorporating our imaging and visual biology assays in high-content, high-throughput screening. The lab is running multiple screening lines in parallel, using screen-to-cloud architecture to process data at ultra-high speeds. Millions of visual biology images are uploaded to the cloud for analysis by the mRNA image network, our visual biology LLM, MOAi technology, and the Lightning co-pilot.

Visual Biology Lightning
AI Co-pilot
Visual Biology
Image Network
Visual
Biology LLM
mRNA images
High content imaging
High scale automated screening
Plate tower
Robot
Compound library
Massively parallel
Visual Biology lab
Cerebio Bioinformatics algorithms that select signature tRNA pair for an mRNA of interest
TranslationLight High content screening for mRNA translation modulators
Brightny Cloud-based big data AI mRNA image analysis identifies active and selective molecules
Compass Mechanism of action and Target ID identification
Cloud Cloud-based mRNA high scale data analysis identifies active and selective mRNA biology modulators.
mRNA images Billions of mRNA images are uploaded to the cloud server for analysis
High content imaging Billions of mRNA images are uploaded to the cloud server for analysis
High scale automated screening Fully automated screen running 24/7 for 3 weeks
Plate Tower +250,000 diverse drug-like small molecules
Robot Fully automated screen running 24/7 for 3 weeks
Compound library +250,000 diverse drug-like small molecules
mRNA Lightning AI Co-pilot Throughout the discovery and MOA identification process, biologists interact with the system in a natural language
mRNA Image Network Recognizes disease-specific signatures
mRNA Biology LLM Integrates our extensive mRNA biology knowledge and actual experimental outcome
mRNA biology lab Tera-scale automation Conducts high content screening from our optimized library of mRNA modulators
HIGH CONTENT mRNA IMAGING
AI IMAGE ANALYSIS
DRUG DISCOVERY
TARGET DISCOVERY
mRNA Biology AI

Cellular Biology Pathway visualizations

PathwayLight™ enables high-throughput, high-content visualization of hundreds of biological pathways within cells such as translation, RNA regulation, splicing and mRNA localization.

It provides an unparalleled view of cellular biology by capturing cellular markers, activities, and morphology. The platform uncovers end-to-end processes such as translation, RNA regulation, splicing, localization, transport, kinetics, and molecular modifications.

  • Transcription
  • Splicing
  • Alternative splicing
  • Capping
  • Polyadenylation
  • Modification
  • Nuclear Export
  • Transport
  • Localization
  • Stability
  • Decay
  • Translation

Disease Signature

The mRNA image neural network identifies mRNA regulatory pathways that differentiate healthy and diseased cells, identifying the mRNA biology signature of a specific disease and forming the foundation for our target and drug discovery approaches.

Healthy
Diseased
Cellular Pathway
Disease Pathway
Visual Biology Disease Signature Decoded

As the leader in mRNA biology research with a platform that spans multiple applications, Anima has initiated the LightON mRNA Community, which now includes over 5,000 mRNA biology experts and enthusiasts from industry and the academy.

Our running webinar series provides free valuable educational insights, covering the applications of researching mRNA biology for target discovery, drug discovery, and optimization of mRNA vaccines and RNA-based drugs.

mRNA Biology Modulators Pipeline

Anima's wholly-owned pipeline of mRNA biology modulators is in Immunology (Lung fibrosis candidate advancing in preclinical stage), in Oncology (Solid tumors lead compounds entering preclinical stage and additional programs against Lymphoma and Neuroblastoma), in Neuroscience (Alzheimer's disease and Pain). In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.

Indication   Target
Discovery
Optimization
Preclinical
Immunology
Lung fibrosis   1
Multiple fibrosis 2
Multiple fibrosis 3
Undisclosed abbvie logo 4
Oncology
Solid tumors   5
Solid tumors 6
Leukemia 7
Neuroblastoma   8
Solid tumors   9
Undisclosed abbvie logo 10
Undisclosed 11
Neuroscience
Alzheimer   12
Pain   13
Undisclosed 14
Undisclosed takeda logo 15
Undisclosed 16
Huntington   17
Undisclosed lilly logo 18
Undisclosed 19
Undisclosed 20
Area Indication Target
Discovery
Optimization
Preclinical
Immunology Lung fibrosis 1
Multiple fibrosis 2
Multiple fibrosis 3
Undisclosed abbvie logo 4
Oncology Solid tumors 5
Solid tumors 6
Leukemia 7
Neuroblastoma 8
Solid tumors 9
Undisclosed abbvie logo 10
Undisclosed 11
Neuroscience Alzheimer   12
Pain   13
Undisclosed   14
Undisclosed takeda logo 15
Undisclosed 16
Huntington   17
Undisclosed lilly logo 18
Undisclosed 19
Undisclosed 20

16 Peer Reviewed Publications

Coverage

News & Events

  • 

    RNA Leaders Europe Congress 2024

    When:
    Where: Basel, Switzerland

    Anima’s Vice President of Business Development, Gal Gur, Ph.D., will participate in the upcoming congress during in two roundtable sessions, both focused on the topic of, “Target selection – lessons learned from small molecules RNA Biology,” to discuss her learnings from working on target selection in...

    Download Press Release »

  • 

    Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis

    When:

    Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate. This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating Idiopathic Pulmonary Fibrosis (IPF) patients.

    Utilizing its mRNA Lightning™...

    Download Press Release »

  • 

    6th Annual RNA-Targeted Drug Discovery and Development Summit

    When:
    Where: Boston, MA

    Anima Biotech will participate in the 6th Annual RNA-Targeted Drug Discovery and Development Summit taking place in Boston, MA from December 12-14, 2024. Our Vice President of Business Development, Gal Gur, Ph.D., will participate on a panel titled, “Overcoming Key Challenges to Improve Drug Design & Discovery...

    Download Press Release »

    Visit the conference website »